depression

A massive, "everything bubble" will burst in 2025, resulting in a crash and possibly a depression. That’s according to renowned economist Harry Dent. The scenario, while bleak, will present a potentially massive Bitcoin (CRYPTO: BTC) buying opportunity.  “I can tell you one thing:...

Robert Kiyosaki, the author of the best-selling book “Rich Dad Poor Dad,” believes the U.S. economy is definitely in a state of depression. What Happened: On Friday, Kiyosaki took to X, to express his view on the state of the U.S. economy. He stated that the economy was in a state of...

Businessman and author Robert Kiyosaki yet again warned of an impending economic crash, adding that it may actually “turn into a depression.” What Happened: Kiyosaki, known for his self-published personal finance book series “Rich Dad Poor Dad,” in a post on X,...

The U.S. Preventive Services Task Force (USPSTF), an advisory panel, has reaffirmed its recommendation for screening most adults for major depression but has not advised broad screening for suicide risk, despite rising suicide rates, STAT News reports. Depression Screening Recommended, Suicide...

The push to legalize psychedelics in more states may have gotten a new public supporter, with the world’s richest man sharing his thoughts and opinions on the benefits. What Happened: Musk has made several comments on Twitter Inc (NYSE: TWTR) in reference to supporting psychedelics for...

If I asked you to picture someone who uses mushrooms (psilocybin), you would not imagine Larry Campbell, a 74-year-old Canadian Senator who has been in politics for two decades. But, Campbell opened up about his use of mushrooms at the Catalyst Psychedelics Summit in Ontario.  Campbell says he...

This article was originally published on Gokhshtein Media and appears here with permission. Anyone who has dealt with mental health challenges knows they’re no laughing matter. Depression is one mental health condition that gets a lot of press, probably because it’s so...

Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) said zuranolone combined with a standard of care antidepressant met the primary goal of showing rapid and significant reduction in depressive symptoms in a late-stage study. The drug, zuranolone, also met the...

atai Life Sciences (NASDAQ: ATAI) on Thursday announced Invyxis, a new program to accelerate the company’s portfolio of compounds. What Happened: The clinical-stage biotechnology company focused on discovering and developing mental health treatments using psychedelic therapy said...

Pasithea Therapeutics Corp's (NASDAQ: KTTA) subsidiary, Pasithea Clinics, has opened its second London clinic in Marylebone, offering intravenous (IV) ketamine therapy to patients suffering from treatment-resistant mental health issues. What Happened: The Company opened its first U.K. clinic in...

​​​​​Compass Pathways plc (NASDAQ: CMPS) has announced results from Phase 2b trial of COMP360 psilocybin therapy for treatment-resistant depression. The study has achieved its primary endpoint for the highest dose, with a 25mg dose of COMP360 demonstrating a highly statistically...

Atai Life Sciences NV (NASDAQ: ATAI) has launched PsyProtix, a new platform company formed with Chymia LLC, a Duke University biotechnology spinout.  PsyProtix is a precision psychiatry company focused on developing therapeutics for treatment-resistant depression (TRD) and...

Axsome Therapeutics Inc (NASDAQ: AXSM) stock is rising in premarket due to an update for its US marketing application seeking approval for AXS-05 for major depressive disorder (MDD). The FDA informed that it would not meet the target action date of August 22 for the application....

According to a new poll conducted by Hill-HarrisX, 65% of registered voters say psychedelic substances do not have medical use. That’s far more than psychedelic legalization advocates would like, but far less than I would’ve expected. Given nearly 50 years of anti-psychedelics...

Wrapped up in its Q2 earnings release, Axsome Therapeutics Inc (NASDAQ: AXSM) said that on July 30, it received an FDA letter for a marketing application for AXS-05 for the treatment of major depressive disorder (MDD). The letter stated that the deficiencies preclude discussion of...